Acadia Pharmaceuticals (ACAD) EBITDA (2010 - 2026)

Acadia Pharmaceuticals' EBITDA history runs 17 years deep, the most recent figure standing at -$4.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 123.93% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at $5.4 million (down 97.7% YoY), while the FY2025 annual figure was $29.3 million, down 87.3% from the prior year.
• EBITDA was -$4.6 million for Q1 2026 at Acadia Pharmaceuticals, up from -$58.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $153.5 million in Q4 2024 to a low of -$113.0 million in Q1 2022.
• Historically, EBITDA has averaged -$2.4 million across 5 years, with a median of $3.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBITDA plunged 150.84% in 2022, then surged 902.21% in 2024.
• A 5-year view of EBITDA shows it stood at -$46.1 million in 2022, then surged by 175.86% to $34.9 million in 2023, then jumped by 339.28% to $153.5 million in 2024, then slumped by 137.86% to -$58.1 million in 2025, then jumped by 92.06% to -$4.6 million in 2026.
• The last three EBITDA figures came in at -$4.6 million (Q1 2026), -$58.1 million (Q4 2025), and $35.8 million (Q3 2025), per Business Quant data.